DK1551409T3 - Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer - Google Patents
Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancerInfo
- Publication number
- DK1551409T3 DK1551409T3 DK03751032T DK03751032T DK1551409T3 DK 1551409 T3 DK1551409 T3 DK 1551409T3 DK 03751032 T DK03751032 T DK 03751032T DK 03751032 T DK03751032 T DK 03751032T DK 1551409 T3 DK1551409 T3 DK 1551409T3
- Authority
- DK
- Denmark
- Prior art keywords
- gemcitabine
- treatment
- cancer
- combination
- possibly
- Prior art date
Links
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title abstract 6
- 229960005277 gemcitabine Drugs 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000005865 ionizing radiation Effects 0.000 title 1
- 150000003246 quinazolines Chemical class 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 2
- 230000005855 radiation Effects 0.000 abstract 2
- 230000001603 reducing effect Effects 0.000 abstract 2
- 230000008728 vascular permeability Effects 0.000 abstract 2
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0223380.7A GB0223380D0 (en) | 2002-10-09 | 2002-10-09 | Combination therapy |
| PCT/GB2003/004334 WO2004032937A1 (en) | 2002-10-09 | 2003-10-06 | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1551409T3 true DK1551409T3 (da) | 2007-06-11 |
Family
ID=9945538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03751032T DK1551409T3 (da) | 2002-10-09 | 2003-10-06 | Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20060009418A1 (da) |
| EP (1) | EP1551409B1 (da) |
| JP (2) | JP5416328B2 (da) |
| KR (1) | KR101098061B1 (da) |
| CN (1) | CN100363004C (da) |
| AT (1) | ATE357236T1 (da) |
| AU (1) | AU2003269253B2 (da) |
| BR (1) | BR0315088A (da) |
| CA (1) | CA2501651C (da) |
| CY (1) | CY1106601T1 (da) |
| DE (1) | DE60312715T2 (da) |
| DK (1) | DK1551409T3 (da) |
| ES (1) | ES2282656T3 (da) |
| GB (1) | GB0223380D0 (da) |
| IL (1) | IL167633A (da) |
| MX (1) | MXPA05003595A (da) |
| NO (1) | NO330601B1 (da) |
| NZ (1) | NZ538999A (da) |
| PT (1) | PT1551409E (da) |
| SI (1) | SI1551409T1 (da) |
| WO (1) | WO2004032937A1 (da) |
| ZA (1) | ZA200502753B (da) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100881105B1 (ko) | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체 |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| DE60121931T2 (de) | 2000-04-07 | 2007-03-01 | Astrazeneca Ab | Chinazolinverbindungen |
| HU230302B1 (hu) | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| MXPA04007459A (es) | 2002-02-01 | 2005-09-08 | Astrazeneca Ab | Compuestos de quinazolina. |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| WO2004041829A1 (en) | 2002-11-04 | 2004-05-21 | Astrazeneca Ab | Quinazoline derivatives as src tyrosine kinase inhibitors |
| NZ541297A (en) * | 2003-02-13 | 2008-03-28 | Astrazeneca Ab | Combination therapy of ZD6474 with 5-FU or/and CPT-11 |
| ATE508747T1 (de) | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-kit kinase-hemmer |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| BRPI0412426A (pt) * | 2003-07-10 | 2006-09-05 | Astrazeneca Ab | uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente |
| CN100450998C (zh) | 2003-11-11 | 2009-01-14 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| EP1797881B1 (en) | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
| KR20070072543A (ko) * | 2004-09-27 | 2007-07-04 | 아스트라제네카 아베 | Ｚｄ6474 및 이마티닙을 포함하는 병합법 |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| AU2006264620B2 (en) * | 2005-07-06 | 2009-10-22 | Astrazeneca Ab | Combination therapy of cancer with AZD2171 and gemcitabine |
| JP2009502960A (ja) * | 2005-07-27 | 2009-01-29 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ |
| EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
| GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
| DK1971338T3 (da) * | 2005-12-22 | 2011-05-23 | Astrazeneca Ab | Kombination af ZD6474 og pemetrexed |
| EP2036557B1 (en) | 2006-05-18 | 2015-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| CN101511793B (zh) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
| ES2399768T3 (es) * | 2006-09-29 | 2013-04-03 | Astrazeneca Ab | Combinación de ZD6474 y bevacizumab para terapia del cáncer |
| US20100048503A1 (en) | 2007-01-19 | 2010-02-25 | Eisai R & D Management Co., Ltd. | Composition for treatment of pancreatic cancer |
| AU2008211952B2 (en) | 2007-01-29 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| JP5638244B2 (ja) | 2007-11-09 | 2014-12-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
| US20120070368A1 (en) * | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| MX2012014776A (es) | 2010-06-25 | 2013-01-29 | Eisai R&D Man Co Ltd | Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados. |
| MX2013009931A (es) | 2011-04-18 | 2013-10-01 | Eisai R&D Man Co Ltd | Agentes terapeuticos contra tumores. |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| CN106660964B (zh) | 2014-08-28 | 2021-09-03 | 卫材R&D管理有限公司 | 高纯度喹啉衍生物及其生产方法 |
| PL3263106T3 (pl) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Sposób tłumienia goryczy pochodnej chinoliny |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| ES2886107T3 (es) | 2015-06-16 | 2021-12-16 | Prism Biolab Co Ltd | Antineoplásico |
| AU2016309356B2 (en) | 2015-08-20 | 2021-06-24 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| CN106727657A (zh) * | 2016-12-27 | 2017-05-31 | 郑州郑先医药科技有限公司 | 一种治疗糖尿病的西药组合物及应用 |
| CN106619688A (zh) * | 2016-12-27 | 2017-05-10 | 郑州郑先医药科技有限公司 | 一种治疗糖尿病的药物组合物及应用 |
| MX380144B (es) | 2017-02-08 | 2025-03-12 | Eisai R&D Man Co Ltd | Composicion farmaceutica de tratamiento de tumores. |
| CA3061888A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3587500T2 (de) * | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
| US7132458B2 (en) * | 1994-08-10 | 2006-11-07 | Chemaphor Inc. | Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| KR100881105B1 (ko) * | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체 |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| US6953679B2 (en) * | 2000-09-19 | 2005-10-11 | Bristol-Myers Squibb Company | Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| EP1534287A1 (en) * | 2002-08-09 | 2005-06-01 | Astrazeneca AB | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| GB0226434D0 (en) * | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
| NZ541297A (en) * | 2003-02-13 | 2008-03-28 | Astrazeneca Ab | Combination therapy of ZD6474 with 5-FU or/and CPT-11 |
| BRPI0412426A (pt) * | 2003-07-10 | 2006-09-05 | Astrazeneca Ab | uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente |
| KR20070072543A (ko) * | 2004-09-27 | 2007-07-04 | 아스트라제네카 아베 | Ｚｄ6474 및 이마티닙을 포함하는 병합법 |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| AU2006264620B2 (en) * | 2005-07-06 | 2009-10-22 | Astrazeneca Ab | Combination therapy of cancer with AZD2171 and gemcitabine |
| DK1971338T3 (da) * | 2005-12-22 | 2011-05-23 | Astrazeneca Ab | Kombination af ZD6474 og pemetrexed |
| ES2399768T3 (es) * | 2006-09-29 | 2013-04-03 | Astrazeneca Ab | Combinación de ZD6474 y bevacizumab para terapia del cáncer |
| US20100212978A1 (en) * | 2009-02-23 | 2010-08-26 | Wen-Hung Huang | Bicycle with two operation molds |
-
2002
- 2002-10-09 GB GBGB0223380.7A patent/GB0223380D0/en not_active Ceased
-
2003
- 2003-10-06 AT AT03751032T patent/ATE357236T1/de active
- 2003-10-06 DK DK03751032T patent/DK1551409T3/da active
- 2003-10-06 JP JP2004542620A patent/JP5416328B2/ja not_active Expired - Fee Related
- 2003-10-06 CN CNB2003801011766A patent/CN100363004C/zh not_active Expired - Fee Related
- 2003-10-06 MX MXPA05003595A patent/MXPA05003595A/es active IP Right Grant
- 2003-10-06 ES ES03751032T patent/ES2282656T3/es not_active Expired - Lifetime
- 2003-10-06 SI SI200330784T patent/SI1551409T1/sl unknown
- 2003-10-06 BR BR0315088-7A patent/BR0315088A/pt not_active IP Right Cessation
- 2003-10-06 EP EP03751032A patent/EP1551409B1/en not_active Expired - Lifetime
- 2003-10-06 US US10/530,567 patent/US20060009418A1/en not_active Abandoned
- 2003-10-06 AU AU2003269253A patent/AU2003269253B2/en not_active Ceased
- 2003-10-06 NZ NZ538999A patent/NZ538999A/en not_active IP Right Cessation
- 2003-10-06 PT PT03751032T patent/PT1551409E/pt unknown
- 2003-10-06 KR KR1020057005960A patent/KR101098061B1/ko not_active Expired - Fee Related
- 2003-10-06 WO PCT/GB2003/004334 patent/WO2004032937A1/en not_active Ceased
- 2003-10-06 DE DE60312715T patent/DE60312715T2/de not_active Expired - Lifetime
- 2003-10-06 CA CA2501651A patent/CA2501651C/en not_active Expired - Fee Related
-
2005
- 2005-03-24 IL IL167633A patent/IL167633A/en active IP Right Grant
- 2005-03-29 NO NO20051575A patent/NO330601B1/no not_active IP Right Cessation
-
2006
- 2006-01-17 ZA ZA200502753A patent/ZA200502753B/en unknown
-
2007
- 2007-05-17 CY CY20071100670T patent/CY1106601T1/el unknown
-
2009
- 2009-08-14 US US12/541,647 patent/US20100120708A1/en not_active Abandoned
-
2010
- 2010-12-24 JP JP2010287659A patent/JP2011088921A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1703223A (zh) | 2005-11-30 |
| KR101098061B1 (ko) | 2011-12-26 |
| IL167633A (en) | 2013-03-24 |
| WO2004032937A1 (en) | 2004-04-22 |
| AU2003269253B2 (en) | 2007-04-05 |
| CN100363004C (zh) | 2008-01-23 |
| CA2501651A1 (en) | 2004-04-22 |
| KR20050055070A (ko) | 2005-06-10 |
| MXPA05003595A (es) | 2005-06-03 |
| ATE357236T1 (de) | 2007-04-15 |
| US20060009418A1 (en) | 2006-01-12 |
| NZ538999A (en) | 2008-02-29 |
| NO20051575L (no) | 2005-04-25 |
| EP1551409B1 (en) | 2007-03-21 |
| DE60312715T2 (de) | 2007-12-06 |
| NO330601B1 (no) | 2011-05-23 |
| BR0315088A (pt) | 2005-08-16 |
| DE60312715D1 (de) | 2007-05-03 |
| JP5416328B2 (ja) | 2014-02-12 |
| GB0223380D0 (en) | 2002-11-13 |
| AU2003269253A1 (en) | 2004-05-04 |
| EP1551409A1 (en) | 2005-07-13 |
| ZA200502753B (en) | 2006-03-29 |
| CA2501651C (en) | 2011-02-15 |
| HK1078771A1 (en) | 2006-03-24 |
| JP2006504723A (ja) | 2006-02-09 |
| PT1551409E (pt) | 2007-05-31 |
| ES2282656T3 (es) | 2007-10-16 |
| CY1106601T1 (el) | 2012-01-25 |
| JP2011088921A (ja) | 2011-05-06 |
| SI1551409T1 (sl) | 2007-08-31 |
| US20100120708A1 (en) | 2010-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1551409T3 (da) | Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer | |
| NO20082567L (no) | Kombinasjon av ZD6474 og pemetrexed | |
| MXPA04004355A (es) | Tratamiento de combinacion que comprende zd6474 y un taxano. | |
| MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
| MX2007003506A (es) | Terapia de combinacion de cancer que comprende azd2171 e imatinib. | |
| NO20082566L (no) | Kombinasjon av AZ2171 og permetrexed | |
| MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
| DK1653964T3 (da) | Cancerkombinationsterapi omfattende AZD2171 og ZD1839 | |
| NO20064755L (no) | Kombinasjonsterapi | |
| NO20056171L (no) | Kombinasjonsterapi | |
| NO20064754L (no) | Kombinasjonsterapi | |
| NO20051601L (no) | Kombinasjonsterapi med gemcitabin og zd6126 |